Phoenix, United States
Founded in 2018, OncoMyx Therapeutics is a biotechnology startup based in the United States, focused on pioneering a new horizon in the field of cancer treatment. With the slogan "We are developing myxoma virotherapies to expand the effectiveness of immunotherapies in the treatment of cancer," OncoMyx leverages a proprietary oncolytic virus, myxoma (MYXV), known for its systemic delivery through human leukocytes to target both hematologic and solid tumors. This novel approach springs from two decades of research led by Professor Grant McFadden, who sequenced the myxoma virus genome back in 1999.
Supported by a $50.00M Series B investment secured on 09 December 2021, the company enjoys backing from prominent investors like B Capital Group, Korea Investment Partners, and Boehringer Ingelheim Venture Fund, among others. This funding underscores the confidence in their groundbreaking work targeting cancers such as myeloma and AML, which holds strong potential to revolutionize cancer therapy efficacy.
